Swiss drug maker Novartis is likely to face legal action for allegedly faking documents to seek registration of its veterinary product Tiamulin Hydrogen Fumarate (80 per cent granules) in India. The drug regulator, Drugs Controller General of India (DCGI), has already cancelled the company’s import licences as well as existing registration certificate for the product.“Our application for the renewal or re-registration of Tiamulin Hydrogen Fumarate (80 per cent granules) has been rejected by the DCGI.